Ten63 Therapeutics
Ten63 Therapeutics is an AI-driven drug-discovery company spun out of Duke University in 2019 and operating from San Francisco, Durham and Boston. It builds BEYOND, which the company describes as the world's first Large Quantum Chemistry Model — pairing generative chemistry at scale (Move37) with a quantum-accurate forcefield and molecular-dynamics engine (Astrolabe) in an approach it calls Superlearning. BEYOND is used to design therapeutics for previously undruggable and under-drugged targets, with an internal pipeline focused on oncology and platform partnerships such as the multi-target collaboration with Boehringer Ingelheim. Ten63 is a therapeutics company, not a software vendor: it publishes no developer program, no public API, and no machine-readable API contract. It does publish an llms.txt describing the company and platform for AI agents.
Ten63 Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Artificial Intelligence.
Ten63 Therapeutics’ developer surface includes support and 4 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 1
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.